From the half-year year report for 31 Dec 2021, dated Feb 25:
July:Agreement signed with Doctors on Demand
August: Agreementsigned with Medgate
August: Agreementsigned with Alodokter
November: Non-exclusive licensing agreement signed with Janssen Pharmaceutica
November: Jointdevelopment and pilot agreement with Carepath Technologies
November: TGAclearance and CE mark certification for cough counter, being used byAstraZeneca
December: 3-yeardistribution agreement signed with Sanrai International
January: Signedbinding LOI with Homify.
February: Signed2-year non-exclusive agreement with Health Teams Pty Ltd
The Directors believe that the Group has been successful in building a long-term business founded on strong technology. If theGroup is unable to manage cash inflows and outflows at amounts as necessary to meet future operating plans, there is a material uncertainty whether the Group will be able to continue as a going concern.
The Directors are confident that they will be able to generate cash flows that will provide sufficient funding to enable the group to continue to be able to pay its liabilities as and when it falls due for a period in excess of12months from the date the financial report has been signed.
The clause about material uncertainty whether the Group will be able to continue as a going concern is pretty much boiler plate:
From the half-year year report for 31 Dec 2021, dated Feb...
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.2M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| RAP (ASX) Chart |
Day chart unavailable